Oncology Based in-Vivo CRO Market Report 2026

The oncology based in-vivo cro market size has grown rapidly in recent years. It will grow from $1.5 billion in 2025 to $1.66 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increasing demand for preclinical oncology studies, growth of animal model-based research, rising prevalence of blood cancers and solid tumors, expansion of contract research organizations globally, increasing regulatory requirements for preclinical validation.

The oncology based in-vivo cro market size is expected to see rapid growth in the next few years. It will grow to $2.54 billion in 2030 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to rising focus on patient-derived xenograft models, increasing integration of digital data management systems, growth in personalized oncology drug development, rising outsourcing of in-vivo studies to specialized CROs, increasing adoption of automated imaging and monitoring solutions. Major trends in the forecast period include rising adoption of digital platforms for in-vivo study management, increasing use of ai and machine learning in preclinical oncology research, growing implementation of genomic profiling for patient-derived xenograft models, rising automation in in-vivo testing and data analysis, increasing iot-enabled monitoring of laboratory equipment and study outcomes.

The increasing prevalence of cancer is expected to drive the growth of the oncology-based in-vivo CRO market in the coming years. Cancer encompasses a group of diseases in which abnormal cells divide uncontrollably, exceed their normal boundaries, originate in nearly any organ or tissue, and spread through the blood and lymph systems to other parts of the body. The diagnosis and treatment of cancer require innovative drugs and devices, which undergo preclinical and clinical trials as well as regulatory evaluation before reaching the market. An oncology in-vivo CRO is a contract research organization hired by a sponsor company to conduct all or part of preclinical in-vivo studies, testing potential therapies in living organisms such as animals, plants, or whole cells before human trials. As cancer prevalence rises, the demand for innovative therapies and treatments has increased, fueling the expansion of the oncology-based in-vivo CRO market. For example, in April 2024, the American Cancer Society, a US-based non-profit organization, reported approximately 609,000 cancer-related deaths and 1.9 million new cancer cases in 2022. Estimates indicate about 620,000 cancer deaths in 2024, representing a slight increase in mortality rates. The growing burden of cancer is therefore supporting the growth of the oncology-based in-vivo CRO market.

Key companies in the oncology-based in-vivo CRO market are concentrating on the development of advanced solutions such as CAR T-cell therapies to strengthen their competitive position. CAR T-cell therapy is an immunotherapy approach that modifies T cells to specifically target and attack cancer cells. For instance, in May 2023, Seattle Children’s Hospital and Research Institute, a US-based organization, launched BrainChild Bio to accelerate CAR T-cell therapies for pediatric brain tumors. The initial target for BrainChild Bio’s CAR T-cell therapy is diffuse intrinsic pontine gliomas (DIPG), a currently incurable childhood brainstem tumor. BrainChild Bio serves as a next-generation CAR T-cell treatment platform that leverages synthetic technologies to maximize the efficacy of CAR T-cell therapies against central nervous system malignancies. The platform plans to extend its innovative CAR T-cell treatments to other challenging adult and pediatric brain tumors, including glioblastoma and brain metastases, following pediatric approval for DIPG.

In March 2023, ClinChoice Medical Development, a US-based contract research organization providing services to accelerate drug and device approvals, acquired Cromsource S.r.l. for an undisclosed amount. This acquisition expands ClinChoice’s operational capacity by adding delivery hubs to complement its existing network across Europe and the US. It also enhances data science capabilities in areas such as risk-based monitoring and decentralized clinical trials. Cromsource S.r.l., based in Italy, is a contract research organization offering comprehensive research services to the pharmaceutical, biotechnology, and medical device sectors.

Major companies operating in the oncology based in-vivo cro market are Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, Shanghai Medicilon Inc., Pharmalegacy Laboratories, Oncotest GmbH, Biocytogen LLC.

North America was the largest region in the oncology-based in-vivo CRO market in 2025.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology based in-vivo cro market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oncology based in-vivo cro market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the oncology-based in-vivo CRO market by raising costs for importing laboratory equipment, imaging devices, and specialized reagents, affecting hospitals, rehabilitation centers, and preclinical CRO laboratories primarily in north america, europe, and asia-pacific. While tariffs increase operational expenses, they also encourage local sourcing, investment in domestic preclinical facilities, and development of regional CRO capabilities, which may strengthen supply chains and reduce dependency on imports.

The oncology based in-vivo cro market research report is one of a series of new reports that provides oncology based in-vivo cro market statistics, including oncology based in-vivo cro industry global market size, regional shares, competitors with a oncology based in-vivo cro market share, detailed oncology based in-vivo cro market segments, market trends and opportunities, and any further data you may need to thrive in the oncology based in-vivo cro industry. This oncology based in-vivo cro market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An oncology-based in-vivo contract research organization (CRO) is a company contracted by another organization to carry out all or part of a preclinical in-vivo study - testing involving living organisms such as animals, plants, or whole cells. These services include designing, managing, monitoring, and analyzing in-vivo preclinical results for oncology drugs or devices.

The primary indications addressed by oncology-based in-vivo CROs include blood cancers, solid tumors, and other conditions. Blood cancers originate from blood-forming tissues such as bone marrow and immune system cells, with leukemia, lymphoma, and multiple myeloma being common types. CROs provide in-vivo testing services using blood cancer xenografts and other models to accelerate drug development and support drug and device sponsors in obtaining market approval. The models used by oncology-based in-vivo CROs include syngeneic models, xenografts, patient-derived xenografts (PDX), and other models, which are applied in hospitals and rehabilitation centers.

The oncology-based in-vivo CRO market includes revenues earned by entities by providing preclinical research services such as in-vivo testing via models such as Orthotopic tumor models, tumor passaging, tissue culture models, and others for oncology drugs and devices. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.